Company: BSAAR
Filing Date: 2025-05-27
Form Type: S-1/A
Source: 0001213900-25-047458
Chunk: 18

Company: BEST SPAC I Acquisition Corp.
Filing Date: 2025-05-27
Form: S-1/A
Chunk 18
---
 will be subject to reduced public company reporting requirements. Investing in our securities involves risks. SEE “RISK FACTORS” ON PAGE 45 FOR DISCUSSIONS OF INFORMATION THAT SHOULD BE CONSIDERED WITH AN INVESTMENT IN OUR SECURITIES. Investors will not be entitled to protections normally afforded to investors in Rule 419 blank check offerings.

|          |     | Price to 
 Public   |            |     | Underwriting      
 Discounts and     
 Commissions(1)(2) |         |     | Proceeds, 
 before    
 expenses, 
 to us     |            |
|:---------|:----|:---------|-----------:|:----|:------------------|--------:|:----|:----------|-----------:|
| Per Unit |     | $        |      10.00 |     | $                 |    0.10 |     | $         |       9.90 |
| Total    |     | $        | 55,000,000 |     | $                 | 550,000 |     | $         | 54,450,000 |

____________ (1)We have also agreed to issue to Maxim and/or its designees, 247,500 ordinary shares (or 284,625shares if the underwriter’s over -allotmentoption is exercised in full), which we refer to herein as the “Representative’s Shares”, as part of representative compensation, which will be issued upon the consummation of this offering. These shares are being registered in the registration statement of which this prospectus forms a part. See the section entitled “Underwriting” of this prospectus for additional information regarding compensation payable to the underwriters. (2)We have agreed to pay Maxim, a fee equal to (i) 1.0% of the gross proceeds of the offering raised by the underwriters, and (ii) 0.5% of the gross proceeds of the offering raised from investors that are introduced solely by us, provided, however, that investments from such investors to which this reduced discount shall apply shall be capped at an aggregate amount of $5 million. Underwriting discounts to be paid by us are calculated based on the assumption that no investors in this offering are introduced by us. Of the proceeds we receive from this offering and the sale of the private placement units described in this prospectus, $55,000,000 or $63,250,000 if the underwriters’ over -allotmentoption is exercised in full ($